Concepedia

Author

Michel Dréano

Merck Serono (Switzerland)

Also Known As

M Dreano, M. Dreano, Michel Dreano, Michel Dréano

52

Publications

2K

Citations

24

H-Index

80

Concepts

All Affiliations

Merck Serono (Switzerland)InsermInstitut PasteurOno Pharmaceutical (United States)University of Miami
MD

About

Michel Dréano is an author at Merck Serono (Switzerland) specializing in medicine, immunology, and cell biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

20

893

2

Natural Sciences

4

4

163

3

Allergy

2

2

52

4

Engineering

1

1

195

5

Health Sciences

1

1

11

Michel Dréano

×

31

Publications

1.9K

Citations

23

H-Index

YearCitations

Characterization of the major histocompatibility complex class II binding site on LAG-3 protein

Bertrand Huard, Renato Mastrangeli, Philippe Prigent,

Proceedings of the National Academy of Sciences

1997

299

Crystal structure of inhibitor of κB kinase β

Guozhou Xu, Yu-Chih Lo, Qiubai Li,

Nature

2011

195

Structural predictions for the ligand-binding region of glycoprotein hormone receptors and the nature of hormone–receptor interactions

Xuliang Jiang, Michel Dréano, David R. Buckler,

Structure

1995

188

Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses

Philippe Prigent, Samir El mir, Michel Dréano,

European Journal of Immunology

1999

90

Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices

Marina Pizzi, Ilenia Sarnico, F. Boroni,

Molecular and Cellular Neuroscience

2003

90

Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis

Naiara Beraza, Yann Malato, Sara Vander Borght,

Gut

2008

86

High-level, heat-regulated synthesis of proteins in eukaryotic cells

Michel Dréano, Jean Brochot, André Myers,

Gene

1986

77

AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-α in Jurkat leukemic cells

Catherine Frelin, Véronique Imbert, Emmanuel Griessinger,

Oncogene

2003

68

Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity

Noëlle Callizot, Emile Andriambeloson, Jonathan D. Glass,

Cancer Chemotherapy and Pharmacology

2008

61

NF‐κB inhibition triggers death of imatinib‐sensitive and imatinib‐resistant chronic myeloid leukemia cells including T315I Bcr‐Abl mutants

Nadia Lounnas, Catherine Frelin, Nadège Gonthier,

International Journal of Cancer

2009

59

Page 1